Sophiris reports top-line extension data for BPH candidate
This article was originally published in Scrip
Sophiris Bio has released positive top-line data from the 12-month follow-up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia (BPH) in the Phase IIb TRIUMPH study.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.